CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer
复制标题
DOI：
10.1634/theoncologist.2017-0674
复制
发表时间：
2018-09-01
期刊：
影响因子：
5.8
通讯作者：
Ferris, Robert L.
中科院分区：
文献类型：
--
作者：
Gillison, Maura L.;Blumenschein, George;Ferris, Robert L.
在对复发性或转移性 (R/M) 头颈鳞状细胞癌 (SCCHN) 患者进行随机、开放标签、3 期 CheckMate 141 的初步分析中，纳武单抗与研究者选择的化疗 (IC) 相比，显着改善了总生存期 (OS)。在这里，我们报告纳武单抗的 OS 益处在最短 11.4 个月的随访中得以维持。此外，在辅助或原发性（即放疗）局部晚期疾病接受铂类治疗取得进展后，接受 R/M SCCHN 一线治疗的患者中，纳武单抗相对于 IC 的 OS 获益也得到了证实。
Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.